Coronary stenting is not the same as a permanent cure after stenting; both interventional techniques (including endovascular stents) and bypass surgery are a palliative treatment for the later stages of coronary artery disease. Restenosis after successful intervention has always been a major limitation of this technology. In the early years of technology development when only balloon dilatation was available, the restenosis rate was as high as 30%-50% at 3-6 months after treatment; the application of stents has reduced the restenosis rate to 15%-20%, and the new generation of drug-coated stents is expected to reduce the restenosis rate to an even lower degree. However, the new generation of stents has been introduced for a short period of time, and its scope of application and long-term efficacy and problems have to be evaluated, so it is not advisable to jump on the bandwagon. More importantly, even if local restenosis is reduced to zero by interventional therapy, because atherosclerosis is a systemic disease, not a localized disease, new lesions may appear in the future in other parts of the same vessel beyond the lesion, and in other vessels supplying the myocardium that do not yet have obvious lesions. Patients with coronary artery disease are also more likely than the general population to develop atherosclerotic disease of the brain, lower extremities, and renal arteries. In fact, intervention and bypass are mainly means to solve the symptoms and ischemia, and only by combining the above preventive measures and preventive medications can the disease be blocked or delayed from the source. Stenting and bypassing are by no means a “once and for all” solution; prevention is a lifelong task. The first follow-up visit 2-3 weeks after stent surgery will review the relevant laboratory tests and adjust the dosage of medication according to the patient’s individual situation. It is important to keep in mind that the dosage of many coronary medications is not fixed, such as statins, angiotensin-converting enzyme inhibitors, and beta-blockers. Moreover, each drug may have side effects on the organism, which should be followed up and monitored. For example, statins may trigger side effects such as elevated liver enzymes. Of course, stent surgery can not be everything, not all patients with coronary heart disease need, or are able to stent implantation treatment, before and after the procedure need to be evaluated by a professional doctor, and, stent surgery, not once and for all, strict drug therapy plus stent implantation, is the fundamental treatment of coronary heart disease.